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The Effect of Endogenous Modulator Endobain E
on NMDA Receptor Is Interfered by Zn2 but
Is Independent of Modulation by Spermidine
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A brain endogenous factor, termed endobain E, allosterically decreases [3H]dizocilpine binding to
NMDA receptor. Such effect depends on receptor activation by the coagonists glutamate and glycine
and is interfered by channel blockers, suggesting its interaction with the inner surface of the asso-
ciated channel. To further analyze endobain E effect on NMDA receptor, in the current study com-
petitive [3H]dizocilpine binding assays to brain membranes were performed with Zn2 to block the
associated channel, as well as with spermidine (SPD), which exerts positive allosteric modulation
of NMDA receptor. Partially or nonadditive effects on [3H]dizocilpine binding were recorded,
respectively, in the presence of endobain E at a concentration that inhibits binding 25% plus IC25
Zn2 or endobain E at a concentration that inhibits binding 50% plus IC50 Zn
2. With an endobain
E concentration that decreases 25% ligand binding, SPD potentiated binding over a wide concen-
tration range but failed to modify endobain E effect. Similarly, [3H]dizocilpine binding reduction
over a wide endobain E concentration range remained unaltered by high SPD concentrations. Addi-
tive effects were observed with endobain E at a concentration that decreases binding 25% plus
IC25 SPD site antagonists arcaine or ifenprodil. Zn
2 experiments indicated that endobain E effect
is interfered by channel blockade produced by this ion. Although endobain E effect is dependent
on NMDA receptor activation by glutamate and glycine, it proves independent of the positive mod-
ulation exerted by SPD. Thus the endogenous modulator seems not to interact at NMDA receptor
polyamine site, favoring the hypothesis that endobain E binds inside the associated channel.
KEY WORDS: NMDA receptor; spermidine; polyamine site; endobain; dizocilpine binding; endogenous mod-
ulator; receptor modulation; zinc ion.
Ca2; an NMDA recognition domain with high affinity
for L-glutamic acid; a glycine recognition domain
insensitive to strychnine; and a polyamine recognition
domain. Coagonists glutamate and glycine activate the
NMDA receptor, leading to channel opening followed
by intracellular Ca2 increase. Substances such as
dizocilpine, ketamine, and Mg2 block Ca2 influx by
binding inside the receptor associated channel (1).
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INTRODUCTION
NMDA receptor is a subclass of glutamatergic
ionotropic receptor sensitive to the exogenous agonist
N-methyl-D-aspartic acid (NMDA). This receptor is
an ionophore complex consisting of at least four dif-
ferent domains: an ion channel domain permeable to
3 Address reprint requests to: Dr. Georgina Rodríguez de Lores Arnaiz,
Instituto de Biología Celular y Neurociencias “Prof. E. De Robertis,”
Facultad de Medicina, Universidad de Buenos Aires, Paraguay 2155,
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The NMDA receptor is modulated by several
endogenous substances, evidencing the importance of
fine-tuning for this receptor function (2–4). In addition,
many of the allosteric modulators provide tonic inhibi-
tion under physiological conditions, suggesting that
allosteric regulation can protect against the damage
resulting from NMDA receptor overactivation (2). One
example is NMDA receptor inhibition by Zn2 through
both voltage-dependent and voltage-independent mecha-
nisms (5, 6). On the other hand, polyamines are positive
allosteric modulators of NMDA receptor able to stimu-
late its function by favoring channel opening in the pres-
ence of receptor coagonists glutamate and glycine (2).
The isolation of an endogenous brain Na,K-
ATPase inhibitor, termed endobain E, which shares
several biological properties with ouabain, such as high-
affinity [3H]ouabain binding blockade (7) and norepi-
nephrine release (8), has been described. Endobain E has
low Mr (1000), is highly hydrophilic, nonlipidic, non-
peptidic, and anionic (9,10).
It was observed that endobain E allosterically
decreases [3H]dizocilpine binding to NMDA receptor, an
effect dependent on receptor activation by glutamate and
glycine. As endobain E effect is interfered by ketamine
and Mg2, the suggestion that this factor modulates
NMDA receptor, most likely by binding inside the asso-
ciated channel, has been advanced (11,12).
The aim of the present study was to evaluate the
influence of Zn2 and polyamine spermidine (SPD), two
NMDA receptor modulators, on [3H]dizocilpine binding
reduction by endobain E.
EXPERIMENTAL PROCEDURE
Animals. Male Wistar rats, 130–160 g weight, were used. All stud-
ies described were conducted in accordance with the Guide for Care and
Use of Laboratory Animals provided by the National Institutes of Health,
USA. Reagents were analytical grade. ZnCl2 was from Merck
(Darmstadt, Germany); Sephadex G-10, arcaine, ifenprodil, SPD, and
2,5-diphenyloxazol (PPO) were from Sigma Chemical Co. (St. Louis,
MO, USA); Sephadex G-50 (fine grade) was from Pharmacia Fine Chem-
icals (Uppsala, Sweden); unlabeled dizocilpine maleate [()-MK-801
hydrogen maleate, ()-5-methyl-10,11-dihydro-5H-dibenzo[a,d]cyclo-
hepten-5,10-imine hydrogen maleate], were from Research Biochemicals
International, Inc. (Natick, MA, USA); [3H]dizocilpine, with a specific
radioactivity of 884.3 GBq/M  103, was purchased from New England
Nuclear, Du Pont (Boston, MA, USA).
Preparation of Crude Cerebral Cortex Membranes. Cerebral cor-
tices from five rats were harvested, dropped into cold 0.32 M sucrose,
and processed following Ogita and Yoneda (13), with modifications. Tis-
sues were homogenized at 10% (w/v, original tissue) for two 1-min peri-
ods in 0.32 M sucrose (neutralized to pH 7 with Tris base solution) using
a Teflon glass homogenizer of the Potter-Elvehjem type, and centrifuged
at 900  g for 10 min. The resultant supernatants were ultracentrifuged
at 100,000  g for 30 min in a 70.1 rotor of an L8-Beckman ultracen-
trifuge. Pellets were washed by resuspension in redistilled water at 10%
(w/v, original tissue) and spun down (100,000  g for 30 min). This
process was then repeated twice. Pellets were resuspended in 50 mM
Tris-HCl buffer, pH 7.4, at 10% (w/v, original tissue), incubated with
gentle stirring at 23°C for 30 min, spun down at 100,000  g for 30 min
and stored at 70°C after resuspension in 0.32 M sucrose; hereafter,
they are termed “resuspended” membranes.
Membrane Treatment. On the day of the binding assay, mem-
branes stored at 70°C after resuspension in sucrose were thawed and
spun down at 100,000  g for 30 min. Pellets were washed succesively
by resuspension in redistilled water (at 10%, w/v) and in 50 mM Tris-
HCl buffer, pH 7.4, and centrifuged at 100,000  g for 30 min. Resul-
tant pellets were homogenized in water to reach a final concentration
of 10 mg protein/ml and processed for ligand binding.
To study NMDA receptor polyamine site, membranes were treated
with Triton X-100, according to Yoneda et al. (14), with modifications.
Membrane samples were unfrozen, spun down at 100,000  g for 30 min
and pellets resuspended in 0.08% Triton X-100 at 0.32 mg protein/ml,
and incubated with gentle stirring at 0–4°C for 10 min. Treatment was
stopped by centrifugation at 100,000  g for 30 min. Resultant pellets
were washed twice by resuspension at 10% (w/v) in 50 mM Tris-HCl
buffer, pH 7.4, and centrifuged at 100,000  g for 30 min; hereafter,
they are termed “Triton-treated” membranes. Resultant pellets were
homogenized in water to reach a final concentration of 4 mg protein/ml
and processed for ligand binding.
Preparation of II-E Fraction (Endobain E). Peak I and II fractions
from rat cerebral cortex were prepared as previously described (9,15).
Thus, for each preparation, cerebral cortices from five rats were pooled,
homogenized at 25% (w/v) in redistilled water, and centrifuged at
100,000  g for 30 min at 4°C in a 70.1 rotor of an L8-Beckman ultra-
centrifuge. A 5-ml supernatant sample (brain-soluble fraction) was taken
to pH 7.4 with 0.1 M NH4HCO3 and loaded on a Sephadex G-10 col-
umn (1  20 cm) and a single 11 ml fraction collected. This filtrate was
then applied to a column packed with Sephadex G-50 (1.8  25 cm).
For gel equilibration and elution, 0.01 M NH4HCO3 was used. Fractions
of 1.4 ml each at a flow rate of 0.3 ml/min were collected in an Gilson
Fraction Collector 202. The absorbance profile was recorded at 280 nm.
Peaks I and II were made up with the fractions presenting maximal UV
absorbance. Peak I was made up with fractions 19–23 but not used in
this study; peak II was made up with fractions 48–52. Peak II was
adjusted to pH 2.0 with 2 M HCl, lyophilized, and stored at 20°C. The
following day, peak II samples were processed by anionic exchange
HPLC on a Synchropak AX-300 column, 250  4.6 mm (Synchrom Inc.,
Lafayette, IN, USA) and eluted at a flow rate of 0.5 ml per min with a
20-min gradient from 0.001 to 0.010 M NH4HCO3 to separate fractions
II-A to II-H. Fractions were collected by monitoring of absorbance
curves at 230 nm; II-E was collected at 12–13 min, then lyophilized, and
used within 20 days (9). Lyophilized II-E samples were dissolved in
0.006 M HCl (at a concentration of 4 mg original tissue per l) and
immediately before assay neutralized with 0.2 M Tris base solution.
Hereafter, II-E fraction is termed endobain E.
[3H]Dizocilpine Binding Assay. Ligand binding to membranes was
performed according to Yoneda et al. (14), with modifications. Tripli-
cate membrane aliquots were processed according to current techniques
(14,16). Aliquots of resuspended membranes or Triton X-100 treated
membranes were incubated in 50 mM Tris-HCl buffer, pH 7.4 (0.25 ml
final volume), at 30°C for 30 min in the presence of 4 nM
[3H]dizocilpine, 1  105 M glutamate and 1  108 M glycine. Pro-
tein concentration during incubation (in milligrams per milliliter) was
0.40–0.80 or 0.16–0.30 for resuspended and Triton X-100 treated
membranes, respectively. When specified, incubation proceeded in the
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Fig. 1. The effect of endobain E on [3H]dizocilpine binding to NMDA
receptor in the presence of Zn2. Resuspended membranes were incu-
bated with 4 nM [3H]dizocilpine, 1  105 M glutamate plus 1 
108 M glycine, with or without 2.5  104 or 5  104 M Zn2, in
the absence or presence of endobain E (1 l equivalent to 4 mg orig-
inal tissue). Results are expressed as percentage [3H]dizocilpine bind-
ing (mean  SD; n  4–8) taking as 100% values obtained without
additions. aP  .05; bP  .01; cP  .001 versus corresponding control
without Zn2 or endobain E, by two-tailed Student’s t test for unpaired
samples. ns, nonsignificant differences between bars, by two-tailed
Student’s t-test for unpaired samples.
presence of SPD, polyamine site antagonists arcaine or ifenprodil, Zn2
and/or endobain E. In each experiment, samples containing 100 M
unlabeled ()-dizocilpine were processed to determine nonspecific
binding, which attained 10%–17% of total binding. Incubation was
stopped with 3 ml cold 50 mM Tris-HCl buffer, pH 7.4, and samples
vacuum-filtered through Whatman GF/B glass disks. Filters were rinsed
twice with 3 ml of ice-cold buffer and retained radioactivity measured
in a liquid scintillation spectrometer. As scintillator solution, 0.4% PPO
in toluene was employed.
Protein Measurement. Protein was determined by the method of
Lowry et al. (17) using bovine serum albumin as standard.
Data Analysis. Data are presented as mean values  SD of n
experiments. When appropriate, statistical significance of difference
has been assessed by two-tailed Student’s t test for unpaired samples.
A probability level of P  .05 was considered significant.
RESULTS
Basal [3H]dizocilpine binding was 603  148 and
1632  221 fM/mg protein in resuspended and Triton
X-100–treated membranes, respectively.
Endobain E Effect on [3H]Dizocilpine Binding
in the Presence of Zinc ion
Resuspended membranes were incubated with 4 nM
[3H]dizocilpine, 1  105 M glutamate plus 1  108 M
glycine, with or without 2.5 or 5.0  104 M Zn2
and/or endobain E (equivalent to 80 or 160 mg original
tissue). In a condition in which Zn2 and endobain E
individually decreased 25% ligand binding, 35% bind-
ing reduction was recorded when both substances were
present together, indicating a partially additive effect. In
the simultaneous presence of endobain E and Zn2 at
concentrations that separately decreased binding roughly
50%, only 50% binding reduction was attained indicating
a nonadditive effect (Fig. 1).
[3H]Dizocilpine Binding in the Presence
of Variable SPD or Endobain E Concentrations
Triton X-100–treated membranes were incubated
with 4 nM [3H]dizocilpine, 1  105 M glutamate and
1  108 M glycine, 1  108 M  1  102 M SPD, in
the absence or presence of a fixed endobain E concen-
tration. As expected, ligand binding was enhanced by
polyamine addition in a concentration-dependent
manner, reaching approximately 160% with 1 mM SPD.
Results indicated that the presence of endobain E (equiv-
alent to 80 mg original tissue) decreased ligand binding
Fig. 2. The effect of endobain E on [3H]dizocilpine binding to NMDA
receptor in the presence of several spermidine (SPD) concentrations.
Triton X-100–treated membranes were incubated with 4 nM [3H]dizo-
cilpine, 1  105 M glutamate plus 1  108 M glycine, with or without
1  108  1  102 M SPD, in the absence or presence of endobain E
(equivalent to 80 mg original tissue). Results are expressed as percentage
[3H]dizocilpine binding (mean  SD; n  3–5) taking as 100% values
obtained without SPD or endobain E addition. Inset, results of binding
in the presence of endobain E versus control for each SPD concentration.
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Fig. 4. The effect of endobain E on [3H]dizocilpine binding in the
presence of arcaine or ifenprodil, competitive and noncompe-
titive antagonists for NMDA polyamine site, respectively. Triton
X-100–treated membranes were incubated with 4 nM [3H]dizocilpine,
1  105 M glutamate plus 1  108 M glucine, 1  103 M SPD,
with or without endobain E (equivalent to 80 mg original tissue), 1 
104 M arcaine (A) or 1  105 M ifenprodil (B). Results are
expressed as percentage [3H]dizocilpine binding (mean  SD; n 
3–5) taking as 100% control values for each incubation medium in
the absence of additions. bP  .01; cP  .001 versus corresponding
control without antagonist or endobain E, by two-tailed Student’s t
test for unpaired samples. **P  .01; ***P  .001 between bars, by
two-tailed Student’s t test for unpaired samples.
was also studied in the presence of ifenprodil, a noncom-
petitive antagonist of polyamine site. Assays were per-
formed in a medium containing 4 nM [3H]dizocilpine, 1 
105 M glutamate plus 1  108 M glycine, 1  103 M
SPD, 1  105 M ifenprodil and/or endobain E (equiva-
lent to 80 mg original tissue). The simultaneous presence
Fig. 3. The effect of variable endobain E concentration on [3H]dizo-
cilpine binding in the presence of spermidine (SPD). Triton
X-100–treated membranes were incubated with 4 nM [3H]dizocilpine,
1  105 M glutamate plus 1  108 M glycine, with or without 1 
103 M SPD, in the absence or presence of endobain E (1 l equiva-
lent to 4 mg original tissue). Results are expressed as percentage
[3H]dizocilpine binding (mean  SD; n  3–4) taking as 100% control
values recorded for each incubation medium. aP  .05; bP  .01;
cP  .001 versus corresponding control recorded in the absence of
endobain E, by two-tailed Student’s t test.
throughout and that the endogenous modulator failed to
alter [3H]dizocilpine binding stimulation by SPD (Fig. 2).
The extent of endobain E effect was independent of the
SPD concentration employed (Fig. 2, inset).
To further study SPD plus endobain E effects, Triton
X-100–treated membranes were incubated with 4 nM
[3H]dizocilpine, 1  105 M glutamate and 1  108 M
glycine, with or without 1  103 M SPD and variable
endobain E concentrations (equivalent to 4–360 mg original
tissue). Findings confirm previous observations indicat-
ing that endobain E decreased ligand binding in a con-
centration-dependent manner (11) and showed that 1 mM
SPD failed to alter endobain E effect throughout (Fig. 3).
Endobain E Effect on [3H]Dizocilpine Binding
in the Presence of Polyamine Site Antagonists
Triton X-100–treated membranes were incubated
with 4 nM [3H]dizocilpine, 1  105 M glutamate plus
1  108 M glycine and 1  103 M SPD, with or with-
out 1  104 M competitive polyamine site antagonist
arcaine and/or endobain E (equivalent to 80 mg original
tissue). In the presence of endobain E at a concentration
that alone inhibited roughly 30% ligand binding, 1 
104 M arcaine, which alone decreased 20% [3H]dizo-
cilpine binding, approximately 45% binding reduction
was recorded, indicating an additive effect (Fig. 4A).
[3H]dizocilpine binding to Triton X-100–treated membranes
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of endobain E and ifenprodil, which independently led to
25% reduction in binding, resulted in 50% binding
decrease, indicating an additive effect (Fig. 4B).
DISCUSSION
In the present study we analyzed the influence of
Zn2 and polyamine SPD on the decrease in [3H]dizo-
cilpine binding to NMDA receptor exerted by a brain
endogenous factor termed endobain E. Results showed that
endobain E effect is interfered by Zn2 (at concentrations
known to block the receptor associated channel) but not
by SPD (at concentrations known to exert positive
allosteric receptor modulation), ruling out endobain E
potential interaction at polyamine site and suggesting that
the endogenous factor most likely binds inside the recep-
tor channel, in agreement with findings showing that
ketamine and Mg2, which bind inside the channel, also
interfere with the effect of this endogenous modulator (12).
Zinc ion modulates NMDA receptor by acting at
two different sites, one outside the membrane field and
the other inside the associated channel. At concentrations
as low as 1–10 M, Zn2 binds to the first site leading
to a decrease in channel opening frequency, a voltage-
independent effect. At higher concentrations (100 M),
Zn2 additionally binds to the second site, producing
channel blockade (18). To study the influence of chan-
nel blockade by Zn2 on NMDA receptor modulation by
endobain E, competitive [3H]dizocilpine binding experi-
ments with different concentrations of endobain E and
Zn2 were carried out. The simultaneous presence of
endobain E plus Zn2 (at concentrations known to exert
voltage-dependent receptor blockade) produced a non-
additive effect, suggesting that by binding inside the
NMDA receptor associated channel this ion interferes
with endobain E effect. This result is in line with the
finding that endobain E effect on [3H]dizocilpine binding
to NMDA receptor is dependent on receptor activation
by glutamate and glycine and that endobain E effect is
interfered by ketamine and Mg2 (12).
Polyamines are positive allosteric modulators of
NMDA receptor (2), and potentiate [3H]dizocilpine bind-
ing in Triton X-100–treated membranes, an effect more
sensitive in the presence of glutamate and glycine (13,14).
[3H]dizocilpine binding is potentiated by polyamines by
binding to a site close but different to coagonist gluta-
mate and glycine sites, in such a way that the three sites
are allosterically coupled (19). To analyze polyamine
influence on NMDA receptor modulation by endobain E,
competitive [3H]dizocilpine binding experiments with dif-
ferent concentrations of SPD or endobain E were carried
out. Besides, experiments with polyamine site antagonists
were performed in the absence or presence of the endoge-
nous modulator.
In the presence of SPD, endobain E decreased
[3H]dizocilpine binding; however, the endogenous modu-
lator failed to alter ligand binding potentiation by SPD.
The extent of endobain E effect remained unaltered in the
presence of a wide SPD concentration range. The con-
centration-response curve for endobain E effect was
unchanged by SPD presence. Thus in neither case did SPD
increase or decrease endobain E effect. Arcaine and ifen-
prodil are respectively competitive and noncompetitive
antagonists of the polyamine site. By blocking the SPD
effect on NMDA receptor, these antagonists decrease
[3H]dizocilpine binding to brain membranes (20,21). On
assaying [3H]dizocilpine binding in the simultaneous pres-
ence of endobain E and arcaine or ifenprodil, additive
effects were recorded. Results showed that polyamine
action blockade by these antagonists failed to alter
endobain E effect. These results suggest that endobain E
hardly binds to the polyamine site and that receptor mod-
ulation by SPD fails to modify endobain E effect.
Endobain E and arcaine or ifenprodil were also tested
at conditions that individually decreased 50% [3H]dizo-
cilpine binding, to observe a nonadditive effect (data not
shown). This interference of endobain E effect seems unre-
lated to SPD site blockade. Accordingly, arcaine decreases
glutamate and glycine efficacy and blocks the receptor-
associated channel (22–24). Thus arcaine may well inter-
fere with endobain E effect by decreasing receptor
activation by coagonists and/or by binding to the inner
channel surface. Regarding ifenprodil, it is known that both
high- and low-affinity components are operative in
[3H]dizocilpine binding inhibition by this antagonist,
involving a specific site and the Zn2 site, respectively (20).
Therefore at high concentrations ifenprodil most likely
binds to the Zn2 site, leading to a decrease in the fre-
quency of channel opening as well as in the time the chan-
nel remains open, most likely interfering with endobain E
effect by reducing receptor activation by coagonists.
It should be recalled that NMDA receptor activa-
tion by glutamate and glycine favors endobain E effect
and that antagonists for such coagonist sites interfere
with endobain E effect; in support, a decrease in recep-
tor activation by partial coagonist site blockade
markedly diminished endobain E effect, indicating an
essential requirement of receptor activation by coago-
nists (12). Thus, though dependent on receptor activa-
tion by glutamate and glycine, endobain E effect seems
independent of receptor modulation by SPD.
In agreement with previous findings (25), present
results support the contention that receptor activation by
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polyamines differs from that achieved by coagonists
glutamate and glycine. Receptor activation by these
coagonists enhances [3H]dizocilpine accessibility to its
binding site within the receptor channel (26–28),
increasing both [3H]dizocilpine association and dissoci-
ation rate constants but not ligand binding affinity at
equilibrium (29). At variance, polyamines enhance
[3H]dizocilpine binding at equilibrium (21,25,30), an
effect attributable to allosteric coupling between
polyamine and ligand sites rather than an increase in
[3H]dizocilpine accessibility to its binding site (21).
Other lines of evidence also indicate that NMDA recep-
tor activation by glutamate and glycine differs from that
achieved by polyamines: whereas glutamate itself is able
to activate the receptor, leading to channel opening,
glycine and SPD fail to do so unless glutamate is also
present (19).
In regard to endobain E chemical composition,
HPLC analysis demonstrated the presence of ascorbic
acid as well as that of a second Na,K-ATPase inhib-
itor (10); the former seems unrelated to endobain E
effect on NMDA receptor because commercial ascorbic
acid failed to modify [3H]dizocilpine binding (data not
shown).
SUMMARY
Results obtained with SPD and Zn2 support the
contention that endobain E effect is hardly attributable
to its binding on polyamine site and that this factor most
likely binds inside the receptor-associated channel;
although endobain E effect may be modulated accord-
ing to the degree of channel activation by coagonists, it
is independent of positive allosteric receptor modulation
by SPD. The NMDA receptor possesses negative fine-
tuning mechanisms that control its activity in physio-
logical and pathological conditions (2–4). By acting as
negative allosteric modulators, proton and Zn2 decrease
receptor activity by reducing channel opening. Another
alternative to reduce NMDA receptor activity is to block
the associated channel; on employing several com-
pounds for this purpose, adverse events appeared as a
consequence of basic neuronal function interference (2).
Endobain E seems to bind to the inner channel surface,
acting as a weak receptor channel blocker, so that this
endogenous factor might only block the overactivated
NMDA receptor. An opposite effect by endobain E lead-
ing to an increase in intracellular Ca2 concentration
as a result of Na,K-ATPase inhibition is likewise
tenable; thus further experiments in other systems are
expected to shed light on its final effect.
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